{
    "symbol": "THMO",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-19 17:19:03",
    "content": " As ThermoGenesis, we are moving closer to achieving one -- achieving our goal through leveraging our unique and proprietary automated and semi-automated cell processing technologies, including the CAR-TXpress platform to transition from a device only company to one focused on providing companies and academic institutions in the space with cell-based contract development and manufacturing service or CDMO services. For the quarter ended March 31st, 2022, the company reported a basic and diluted net loss attributable to common stockholders of $1.9 million or $0.16 per share based on approximately 12.3 million shares outstanding."
}